Jul 14, 2026 04:05PM
Jul 14, 2026 04:05PM
May 7, 2026 04:01PM
Mar 30, 2026 04:01PM
Feb 17, 2026 08:00AM
Jan 12, 2026 07:08AM
Jan 12, 2026 07:00AM Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
Jan 8, 2026 08:00AM
Dec 1, 2025 04:17PM
Nov 10, 2025 04:05PM
Aug 14, 2025 04:05PM
Aug 7, 2025 04:31PM
Aug 7, 2025 04:30PM
Jul 24, 2025 07:00AM Annexon completes enrollment in phase 3 trial for dry AMD treatment
Jul 24, 2025 07:00AM
Jun 18, 2025 04:05PM
May 19, 2025 04:07PM
May 19, 2025 04:05PM
May 12, 2025 08:00AM
May 9, 2025 05:00PM
May 7, 2025 08:00AM Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
Apr 9, 2025 07:00AM
Apr 8, 2025 04:05PM
Apr 3, 2025 06:18PM
Mar 3, 2025 08:00AM
Feb 13, 2025 08:30AM
Dec 17, 2024 06:53AM
Dec 16, 2024 07:31AM Annexon (ANNX) Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin or Plasma Exchange
Dec 16, 2024 07:30AM
Dec 5, 2024 08:00AM
Nov 14, 2024 08:00AM
Oct 21, 2024 08:00PM
Oct 15, 2024 08:02AM
Oct 15, 2024 08:00AM
Sep 9, 2024 08:00AM Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress
Aug 13, 2024 09:28AM
Aug 12, 2024 08:00AM
Aug 5, 2024 08:00AM
Jul 11, 2024 06:09PM
Jun 25, 2024 05:00PM
Jun 25, 2024 05:00PM
Jun 18, 2024 08:00AM Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting
Jun 4, 2024 07:00AM
Jun 4, 2024 07:00AM
May 7, 2024 12:30PM
Apr 16, 2024 09:00AM
Mar 26, 2024 04:05PM
Feb 21, 2024 08:00AM
Feb 21, 2024 08:00AM Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach
Dec 20, 2023 05:12PM

325,857 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All